This systematic review identified published studies that evaluated the use of ondansetron in individuals with psychosis associated with dementia.
Methods
A literature search was conducted of PubMed, MEDLINE, EMBASE, PsycINFO, and Cochrane Collaboration databases for randomized controlled trials (RCTs), cohort studies, and case reports that evaluated the use of ondansetron for individuals with psychosis associated with dementia. Bibliographic databases of published articles were also searched for additional studies.
Results
A total of 4 studies were identified, all of which were open-label trials of ondansetron forpsychosis associated with Parkinson's disease. All trials showed improvements in visual hallucinations and paranoid ideations in most patients, as well as a modest improvement in functioning, but no evidence of cognitive improvement.
Conclusions
Ondansetron appears to have benefit in improving positive symptoms of psychosis in individuals with Parkinson's disease, but RCTs are needed before routine use is recommended. There is a paucity of evidence for the use of ondansetron for psychosis associated with other forms of dementia.
Get full access to this article
View all access options for this article.
References
1.
AaltenP, VerheyFR, BozikiM, . Consistency of neuropsychiatric syndromes across dementias: results from the European Alzheimer disease consortium. Part II. Dement Geriatr Cogn Disord.2008;25:1–8.
2.
TripathiM, VibhaD.An approach to and the rationale for the pharmacological management of behavioral and psychological symptoms of dementia. Ann Indian Acad Neurol. 2010;13:(suppl 2)S94–S98.
3.
MintzerJE, MirskiDF, HoernigKS.Behavioral and psychological signs and symptoms of dementia: a practicing psychiatrist's viewpoint. Dialogues Clin Neurosci. 2000;2:139–155.
4.
BallardC, OyebodeF.Psychotic symptoms in patients with dementia. Int J Geriatr Psychiatry. 1995;10:743–752.
5.
BallardC, NeillD, O'BrienJ, . Anxiety, depression and psychosis in vascular dementia: prevalence and associations. J Affect Disord. 2000;59:97–108.
6.
LyketsosCG, LopezO, JonesB, . Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study. JAMA. 2002;288:1475–1483.
7.
WilsonRS, GilleyDW, BennettDA, . Hallucinations, delusions, and cognitive decline in Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2000;89:172–177.
8.
PrinceM, BryceR, AlbaneseE, . The global prevalence of dementia: a systematic review and metaanalysis. Alzheimers Dement. 2013;9:63–75., e2.
9.
SawaGM, ZaccaiJ, MatthewsFE, ; Medical Research Council Cognitive Function and Ageing Study. Prevalence, correlates and course of behavioural and psychological symptoms of dementia in the population. Br J Psychiatry. 2009;194:212–219.
10.
RopackiSA, JesteDVEpidemiology of and risk factors for psychosis of Alzheimer's disease: a review of 55 studies published from 1990 to 2003. Am J Psychiatry.2005;182:2022–2030.
11.
VelakoulisD, WalterfangM, MocellinR, . Frontotemporal dementia presenting as schizophrenialike psychosis in young people: clinicopathological series and review of cases. Br J Psychiatry. 2009;194:298–305.
12.
LauterbachEC.The neuropsychiatry of Parkinson's disease and related disorders. Psychiatr Clin North Am. 2004;27:801–825.
13.
WilkoszPA, SeltmanHJ, DevlinB, . Trajectories of cognitive decline in Alzheimer's disease. Int Psychogeriatr. 2010;22:281–290.
14.
MendezMF, ShapiraJS, WoodsRJ, . Psychotic symptoms in frontotemporal dementia: prevalence and review. Dement Geriatr Cogn Disord. 2008;25:208–211.
15.
Vilalta-FranchJ, López-PousaS, Calvó-PerxasL, . Psychosis of Alzheimer disease: prevalence, incidence, persistence, risk factors, and mortality. Am J Geriatr Psychiatry. 2013;21:1135–1143.
16.
KimJ, SchweizerTA, FischerCE, . The role of cerebrovascular disease on cognitive and functional status and psychosis in severe Alzheimer's disease. J Alzheimers Dis. 2017;55:381–389.
WoltersEC.Intrinsic and extrinsic psychosis in Parkinson's disease. J Neurol.2001; 248(suppl 3): 111,22–27.
19.
HendersonMJ, MeilersJD.Psychosis in Parkinson's disease: ‘between a rock and a hard place? Int Rev Psychiatry. 2000;12:319–334.
20.
Lanctôt KL, HerrmannN, MazzottaP.Role of serotonin in the behavioral and psychological symptoms of dementia. J Neuropsychiatry Clin Neurosci. 2001;13:5–21.
21.
TampiRR, TampiDJ, BalachandranS, . Antipsychotic use in dementia: a systematic review of benefits and risks from meta-analyses. Ther Adv Chronic Dis. 2016;7:229–245.
22.
FernandezHH, TrieschmannME, FriedmanJH.Treatment of psychosis in Parkinson's disease: safety considerations. Drug Saf. 2003;26:643–659.
23.
AlexopoulosGS, StreimJ, CarpenterD, ; Expert Consensus Panel for Using Antipsychotic Drugs in Older Patients. Using antipsychotic drugs in older patients. J Clin Psychiatry. 2004;65:(suppl 2)5–99; discussion 100-102; quiz 103-104.
24.
BallardCG, GauthierS, CummingsJL, . Management of agitation and aggression associated with Alzheimer disease. Nat Rev Neurol. 2009;5: 245–255.
25.
MittalV, KurupL, WilliamsonD, . Risk of cerebrovascular adverse events and death in elderly patients with dementia when treated with antipsychotic medications: a literature review of evidence. Am J Alzheimers Dis Other Demen. 2011;26:10–28.
26.
ChiuY, BeroL, HessolNA, . A literature review of clinical outcomes associated with antipsychotic medication use in North American nursing home residents. Health Policy. 2015;119:802–813.
27.
KalesHC, GitlinLN, LyketsosCG.Assessment and management of behavioral and psychological symptoms of dementia. BMJ. 2015;350:h369. doi: 10.1136/bmj.h369.
28.
MadhusoodananS, TingMB.Pharmacological management of behavioral symptoms associated with dementia. World J Psychiatry.2014;4:72–79.
29.
TampiRR, TampiDJ.Efficacy and tolerability of benzodiazepines for the treatment of behavioral and psychological symptoms of dementia: a systematic review of randomized controlled trials. Am J Alzheimers Dis Other Demen. 2014;29:565–574.
30.
BentleyKR, BarnesNM.Therapeutic potential of serotonin 5-HT3 antagonists in neuropsychiatric disorders. CNS Drugs. 1995;3:363–392.
31.
JohnsonBA, RoacheJD, Ait-DaoudN, . A preliminary randomized, double-blind, placebo-controlled study of the safety and efficacy of ondansetron in the treatment of cocaine dependence. Drug Alcohol Depend. 2006;84:256–263.
32.
JiangJC, GietzenDW.Anorectic response to amino acid imbalance: a selective serotonin3 effect?Pharmacol Biochem Behav. 1994;47:59–63.
33.
NoroozianM, GhasemiS, ModabberniaA, . A placebo-controlled study of tropisetron added to risperidone for the treatment of negative symptoms in chronic and stable schizophrenia. Psychopharmacology (Berl). 2013;228:595–602.
34.
AkhondzadehS, MohammadiN, NoroozianM, . Added ondansetron for stable schizophrenia: a double blind, placebo controlled trial. Schizophr Res. 2009;107:206–212.
35.
CostallB, NaylorRJ.5-HT3 receptors. Curr Drug Targets CNS Neurol Disord.2004;3:27–37.
36.
IkeguchiK, KurodaA.Mianserin treatment of patients with psychosis induced by antiparkinsonian drugs. Eur Arch Psychiatry Clin Neurosci. 1995;244:320–324.
37.
TagaiK, NagataT, ShinagawaS, . Mirtazapine improves visual hallucinations in Parkinson's disease: a case report. Psycho geriatrics. 2013;13:103–107.
38.
CummingsJ, IsaacsonS, MillsR, . Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet. 2014;383:533–540.
39.
TournaKT, TournaDC.Pimavanserin (Nuplazid™) for the treatment of Parkinson disease psychosis: a review of the literature. Mental Health Clinician. 2017;7:230–234.
40.
MoherD, ShamseerL, ClarkeM; PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Systematic Reviews. 2015;4:1.
ZoldanJ, FriedbergG, Goldberg-SternH, . Ondansetron for hallucinosis in advanced Parkinson's disease. Lancet. 1993;341:562–563.
43.
ZoldanJ, FriedbergG, LivnehM, . Psychosis in advanced Parkinson's disease: treatment with ondansetron, a 5-HT3 receptor antagonist. Neurology. 1995;45:1305–1308.
44.
ZoldanJ,FriedbergG,WeizmanA, . Ondansetron, a 5-HT3 antagonist for visual hallucinations and paranoid delusional disorder associated with chronic L-DOPA therapy in advanced Parkinson's disease. Adv Neurol. 1996;69:541–544.
45.
EichhornTE, BruntE, OertelWH.Ondansetron treatment of L-dopa-induced psychosis. Neurology. 1996;47:1608–1609.
46.
FriedbergG, ZoldanJ, WeizmanA, . Parkinson psychosis rating scale: a practical instrument for grading psychosis in Parkinson's disease. Clin Neuropharmacol. 1998;21:280–284.
47.
MelamedE, FriedbergG, ZoldanJ.Psychosis: impact on the patient and family. Neurology. 1999;52:(suppl 3)514–516.
